The purpose of this pilot study is to determine how the anti-platelet drug, ticagrelor, impacts platelet mRNA splicing after a single loading dose in 10 healthy participants. These results will be valuable in that they will help inform our analysis of platelet RNA splicing after a thrombotic event.
There is nothing known on how differential splicing in platelets is impacted by of P2Y12 inhibition by anti-platelet agents. Consequently, the focus of this longitudinal pilot study will be to determine the impact of a single ticagrelor loading dose (180 mg), our "model" anti-platelet drug, on platelet RNA splicing in 10 healthy individuals. It will test the hypothesis that ticagrelor exposure does not significantly alter platelet mRNA splicing. It will involve administering a single loading dose (180 mg) of ticagrelor to healthy volunteers.
Study Type
OBSERVATIONAL
A single loading dose of ticagrelor (180 mg) will be administered to each participant in this study.
The George Washington University School of Medicine and Health Sciences
Washington D.C., District of Columbia, United States
Shenandoah University Bernard J. Dunn School of Pharmacy
Fairfax, Virginia, United States
Measurement of the Change in Platelet Activity From Baseline after Drug Administration
As determined by the VerifyNow P2Y12 Assay
Time frame: Comparison made 2.5 hours following drug administration
Measurement of the Change in Platelet mRNA splicing From Baseline after Drug Administration
As determined by RNAseq analysis
Time frame: Comparison made 2.5 hours following drug administration
Measurement of Ticagrelor Pharmacokinetics After Drug Administration
Drug and its major metabolite levels will be measured by HPLC
Time frame: Comparison made 2.5 hours following drug administration
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.